Walden Group Healthcare M&A Blog

  • Katena Products Acquires Micro-Select Instruments, Inc.

    10/26/2020
    Katena Products, producer of ophthalmic instruments, biologics, and lenses and portfolio company of private equity firm Audax Group, is buying St. Clair, MO-based Micro-Select Instruments, a manufacturer of ophthalmic forceps, needle holders, speculums and other instruments.  The acquisition builds on Katena’s November 2019 purchase of St....
    Read More
  • Steris plc Acquires Key Surgical for $850m

    10/12/2020
    Ireland-based Steris plc, a $3.1b provider of specialty sterilization solutions, equipment processing and endoscope repair services has acquired Key Surgical, a producer of consumables used in minimally-invasive procedures, from private equity firm Water Street.  The acquisition adds OR-focused instruments and other sterile, single-use products...
    Read More
  • QIAGEN Acquires NeuMoDx Molecular for $248m

    9/29/2020
    Netherlands-based QIAGEN N.V. (NYSE: QGEN), a $1.5b developer of molecular diagnostic equipment and assays, has acquired a 80.1% ownership stake in diagnostics instruments maker NeuMoDx Molecular, Inc. for $248m.  Qiagen had purchased a 19.9% ownership stake in NeuMoDx in 2018.  The acquisition builds on QIAGEN’s portfolio of automated...
    Read More
  • Intersect ENT to Acquire Fiagon AG Medical Technologie

    9/25/2020
    Intersect ENT (Nasdaq: XENT), a $109.1m developer of sinus implants and other ENT-focused products is acquiring Germany-based Fiagon, a developer of proprietary, electromagnetic-based ENT surgical navigation systems for $71.2m.  Fiagon’s instruments, produced in Germany, are tip-tracked, enabling surgeons to monitor the full range of...
    Read More
  • Bruker To Acquire Canopy Biosciences

    9/14/2020
    Bruker Corp. (Nasdaq: BRKR), a $2.1b manufacturer of analytical and diagnostic platforms and instruments is acquiring Canopy Biosciences, a developer of multiplex biomarker imaging technologies for immunology, immuno-oncology and cell therapy to boost Bruker’s CRISPR (clustered regularly interspaced short palindromic repeats) gene editing...
    Read More